A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Investigational New Drugs
Smyth, Lillian M LM; Monson, Kelsey R KR; Jhaveri, Komal K; Drilon, Alexander A; Li, Bob T BT; Abida, Wassim W; Iyer, Gopa G; Gerecitano, John F JF; Gounder, Mrinal M; Harding, James J JJ; Voss, Martin H MH; Makker, Vicky V; Ho, Alan L AL; Razavi, Pedram P; Iasonos, Alexia A; Bialer, Philip P; Lacouture, Mario E ME; Teitcher, Jerrold B JB; Erinjeri, Joseph P JP; Katabi, Nora N; Fury, Matthew G MG; Hyman, David M DM